$RLAY
Relay Therapeutics, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021015518 Filed on March 25, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $952.0K $82.65M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.47M $38.59M $3.430M
YoY Change 414.08% 180.86%
% of Gross Profit
Research & Development $30.62M $99.86M $22.41M
YoY Change 41.12% 42.04%
% of Gross Profit
Depreciation & Amortization $919.0K $3.500M $2.180M
YoY Change 6.98% 25.0%
% of Gross Profit
Operating Expenses $43.36M $138.5M $25.83M
YoY Change 63.87% 64.73%
Operating Profit -$42.41M -$55.80M
YoY Change 60.27% -33.61%
Interest Expense $230.0K $3.400M $1.920M
YoY Change -85.35% -61.36%
% of Operating Profit
Other Income/Expense, Net $221.0K $3.384M $0.00
YoY Change -85.94% -61.29%
Pretax Income -$42.18M -$52.41M -$23.91M
YoY Change 69.47% -30.41%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$42.18M -$52.41M -$23.91M
YoY Change 69.51% -30.4%
Net Earnings / Revenue -4431.09% -63.41%
Basic Earnings Per Share -$5.40
Diluted Earnings Per Share -$467.6K -$582.9K -$0.31
COMMON SHARES
Basic Shares Outstanding 90.40M 42.62M
Diluted Shares Outstanding 42.62M

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $726.1M $678.1M
YoY Change 117.27% 90.58%
Cash & Equivalents $262.7M $447.6M $41.95M
Short-Term Investments $463.4M $230.4M
Other Short-Term Assets $7.800M $9.400M
YoY Change 73.33% 100.0%
Inventory
Prepaid Expenses
Receivables $8.600M $82.70M
Other Receivables $0.00 $0.00
Total Short-Term Assets $742.4M $770.1M $360.5M
YoY Change 119.2% 113.62%
LONG-TERM ASSETS
Property, Plant & Equipment $5.907M $28.80M $8.094M
YoY Change -80.76% -9.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $900.0K $900.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $28.91M $29.70M $32.53M
YoY Change -8.51% -8.9%
TOTAL ASSETS
Total Short-Term Assets $742.4M $770.1M $360.5M
Total Long-Term Assets $28.91M $29.70M $32.53M
Total Assets $771.3M $799.8M $393.1M
YoY Change 108.3% 103.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.593M $6.400M $6.991M
YoY Change 39.83% -8.57%
Accrued Expenses $8.867M $7.100M $3.746M
YoY Change 19.82% 51.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.08M $13.60M $11.99M
YoY Change 39.85% 13.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.50M $22.90M
YoY Change -3.43% -3.38%
Total Long-Term Liabilities $22.50M $22.90M
YoY Change -3.43% -3.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.08M $13.60M $11.99M
Total Long-Term Liabilities $22.50M $22.90M
Total Liabilities $38.56M $36.50M $35.73M
YoY Change 10.8% 2.24%
SHAREHOLDERS EQUITY
Retained Earnings -$446.4M -$189.5M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $732.8M $763.3M -$180.4M
YoY Change
Total Liabilities & Shareholders Equity $771.3M $799.8M $393.1M
YoY Change 108.3% 103.46%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$42.18M -$52.41M -$23.91M
YoY Change 69.51% -30.4%
Depreciation, Depletion And Amortization $919.0K $3.500M $2.180M
YoY Change 6.98% 25.0%
Cash From Operating Activities $46.64M -$102.5M -$55.31M
YoY Change -308.83% 54.97%
INVESTING ACTIVITIES
Capital Expenditures $476.0K $1.931M -$4.860M
YoY Change -53.33% -75.87%
Acquisitions
YoY Change
Other Investing Activities -$233.2M $83.60M -$311.0M
YoY Change -553.69% -126.88%
Cash From Investing Activities -$233.6M $81.67M -$315.9M
YoY Change -563.8% -125.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.055M $1.216M
YoY Change 485.47% 98.37%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.055M 426.5M 560.0K
YoY Change 485.47% 7508.08%
NET CHANGE
Cash From Operating Activities 46.64M -102.5M -55.31M
Cash From Investing Activities -233.6M 81.67M -315.9M
Cash From Financing Activities 2.055M 426.5M 560.0K
Net Change In Cash -184.9M 405.7M -370.6M
YoY Change -751.42% -206.89%
FREE CASH FLOW
Cash From Operating Activities $46.64M -$102.5M -$55.31M
Capital Expenditures $476.0K $1.931M -$4.860M
Free Cash Flow $46.16M -$104.4M -$50.45M
YoY Change -297.67% 40.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90399972
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q3 dei Entity Public Float
EntityPublicFloat
2543277454
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
RLAY
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3923475
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
399 Binney Street
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2020 dei City Area Code
CityAreaCode
617
CY2020 dei Local Phone Number
LocalPhoneNumber
370-8837
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
447646000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41954000
CY2020Q4 us-gaap Investments
Investments
230415000
CY2019Q4 us-gaap Investments
Investments
313862000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
75000000
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
7654000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9385000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4720000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
770100000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
360536000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6250000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8094000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22579000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23560000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
878000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
878000
CY2020Q4 us-gaap Other Assets
OtherAssets
22000
CY2020 rlay Deemed Dividend Resulting From Extinguishment Of Preferred Stock
DeemedDividendResultingFromExtinguishmentOfPreferredStock
-177789000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-230201000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-75305000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
325000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-261000
CY2019Q4 us-gaap Assets
Assets
393068000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6991000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3746000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1249000
CY2019Q4 rlay Restricted Stock Liability
RestrictedStockLiability
156000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
537781000
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
4000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8715000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
325000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189482000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-180438000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
393068000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89991324
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4716634
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89906835
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4037476
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
82654000
CY2020 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
rlay:LicenseRevenueMember
CY2020 us-gaap Revenues
Revenues
82654000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
99862000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70306000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38588000
CY2020 us-gaap Operating Expenses
OperatingExpenses
138450000
CY2019 us-gaap Operating Expenses
OperatingExpenses
84048000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-55796000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-84048000
CY2020 us-gaap Interest Income Other
InterestIncomeOther
3400000
CY2019 us-gaap Interest Income Other
InterestIncomeOther
8801000
CY2020 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
16000
CY2019 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
58000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3384000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8743000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-52412000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-75305000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.40
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.82
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42619582
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3450500
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-261000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
325000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52673000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74980000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-110927000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
613000
CY2019 rlay Vesting Of Restricted Common Stock Value
VestingOfRestrictedCommonStockValue
400000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4456000
CY2019 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
325000
CY2020 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
-177789000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
715570000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
425293000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1216000
CY2020 rlay Vesting Of Restricted Common Stock Value
VestingOfRestrictedCommonStockValue
154000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31960000
CY2020 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-261000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
34707000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
31960000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4456000
CY2020 us-gaap Depreciation
Depreciation
3549000
CY2019 us-gaap Depreciation
Depreciation
2845000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
416000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2495000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-56000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4665000
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2123000
CY2020 rlay Increase Decrease In Lease Assets And Liabilities Net
IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet
-571000
CY2019 rlay Increase Decrease In Lease Assets And Liabilities Net
IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet
-1233000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-410000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3000000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2010000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2200000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
75000000
CY2020 us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
7654000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
22000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102489000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66133000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1931000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8002000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
266455000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
553517000
CY2020 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
350058000
CY2019 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
242475000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
81672000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-319024000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
4993000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1216000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
613000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
427800000
CY2020 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
2507000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
426509000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5606000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
405692000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-379551000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42832000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
422383000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
448524000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
519000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
745000
CY2020 rlay Reclassification Of Restricted Stock Liability To Additional Paid In Capital
ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital
153000
CY2019 rlay Reclassification Of Restricted Stock Liability To Additional Paid In Capital
ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital
400000
CY2020 rlay Loss On Extinguishment And Reissuance Of Preferred Stock
LossOnExtinguishmentAndReissuanceOfPreferredStock
-177789000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
715508000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
819000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
24936000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
878000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
878000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under <font style="color:#000000;">Accounting Standards Codification Topic 606, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</font>, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&#8217;s estimates. </p>
CY2019Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
519825000
CY2020Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
23000000
CY2020Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
20.00
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
425293000
CY2020Q3 rlay Underwriting Discounts And Commissions
UnderwritingDiscountsAndCommissions
32200000
CY2020Q3 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
2507000
CY2020Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
61992534
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-3.55092
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 rlay Cash And Cash Equivalents Maturity Date Description
CashAndCashEquivalentsMaturityDateDescription
The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
61992534
CY2020 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
greater than 50%
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
230351000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
64000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
230415000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16780000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15075000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10530000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6981000
CY2020Q4 rlay Accrued External Research And Development Expense Current
AccruedExternalResearchAndDevelopmentExpenseCurrent
5099000
CY2019Q4 rlay Accrued External Research And Development Expense Current
AccruedExternalResearchAndDevelopmentExpenseCurrent
3077000
CY2020Q4 rlay Accrued Professional Services Current
AccruedProfessionalServicesCurrent
464000
CY2019Q4 rlay Accrued Professional Services Current
AccruedProfessionalServicesCurrent
336000
CY2020Q4 rlay Accrued Other Expenses Current
AccruedOtherExpensesCurrent
197000
CY2019Q4 rlay Accrued Other Expenses Current
AccruedOtherExpensesCurrent
333000
CY2020Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
37206604
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
337272859
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
212642857
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
212642857
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
537781000
CY2019Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
59883877
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of the Convertible Preferred Stock had voting rights equivalent to the number of shares of common stock into which their shares of preferred stock would convert. So long as any of the Convertible Preferred Stock was outstanding, a requisite vote of the Convertible Preferred Stockholders, which was defined as a majority of the Convertible Preferred Stockholders, was required to affirm certain corporate actions, which included, but was not limited to, the disposal of assets, the acquisition of assets or a business and the authorization of additional shares of the Company’s capital. In addition, such actions required a requisite vote of the Series C preferred stockholders and a majority vote of the Series B preferred stockholders, if any of the respective preferred stock was outstanding.
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2020 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2019 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020 rlay Common Stock Restriction Period
CommonStockRestrictionPeriod
P4Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
9619000
CY2020Q4 rlay Common Stock Capital Shares Reserved Under Compensation Plan
CommonStockCapitalSharesReservedUnderCompensationPlan
8026772
CY2019Q4 rlay Common Stock Capital Shares Reserved Under Compensation Plan
CommonStockCapitalSharesReservedUnderCompensationPlan
8407169
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8026772
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
68291046
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5306176
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2898663
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
297000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
210781
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7697058
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2148119
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
5548939
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.62
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.90
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.09
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.91
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.99
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.49
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
7.96
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M26D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2020 rlay Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm
P8Y8M26D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3214000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
266050000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
79625000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
186425000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.018
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.735
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.728
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.776
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7347
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.14
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.34
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31960000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4456000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
69948000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M9D
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.070
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.273
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.310
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.076
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.041
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.067
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.009
CY2020 rlay Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.003
CY2019 rlay Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.002
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
48832000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42647000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10270000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6309000
CY2020Q4 rlay Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6430000
CY2019Q4 rlay Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6542000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1469000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1498000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4496000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
534000
CY2020Q4 rlay Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
230000
CY2019Q4 rlay Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
188000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
14000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
13000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
71741000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57731000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
65813000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51537000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
5928000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6194000
CY2020Q4 rlay Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
5928000
CY2019Q4 rlay Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
6194000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5928000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6194000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
174028000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
192346000
CY2020 rlay Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
14276000
CY2019 rlay Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
23307000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
There are currently no pending tax examinations.
CY2020 rlay Tax Cuts And Jobs Act Of2017 Description Of Corporate Tax Payers
TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers
Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.
CY2020 rlay Cares Act Percentage Of Eliminates Of Taxable Income
CARESActPercentageOfEliminatesOfTaxableIncome
0.80
CY2020 rlay Tax Cuts And Jobs Act Of2017 Maximum Percentage Of Interest Deducted By Tax Payers
TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers
0.50
CY2020 rlay Cares Act Percentage Of Interest Deducted By Tax Payers
CARESActPercentageOfInterestDeductedByTaxPayers
0.30
CY2020 rlay Cares Act Percentage Of Corporate Charitable Deduction Limit
CARESActPercentageOfCorporateCharitableDeductionLimit
0.25
CY2020 rlay Cares Act Period Of Qualified Improvement Property For Cost Recovery
CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery
P15Y
CY2020 rlay Cares Act Percentage Of Bonus Depreciation
CARESActPercentageOfBonusDepreciation
1.00
CY2020 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
177789000
CY2020 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-230201000
CY2019 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-75305000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7781547
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65869211
CY2015Q4 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2020Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
878000
CY2020 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2028-09-30
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
rlay:OperatingLeaseAssetsMember
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
rlay:OperatingLeaseAssetsMember
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
rlay:OperatingLeaseLiabilitiesMember
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
rlay:OperatingLeaseLiabilitiesMember
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
rlay:OperatingLeaseLiabilitiesNetOfCurrentPortionMember
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
rlay:OperatingLeaseLiabilitiesNetOfCurrentPortionMember
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24422000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24832000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4021000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
3797000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
4878000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
2602000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3985000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4134000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4254000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4377000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4503000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
15959000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37212000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12790000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
590000

Files In Submission

Name View Source Status
0001564590-21-015518-index-headers.html Edgar Link pending
0001564590-21-015518-index.html Edgar Link pending
0001564590-21-015518.txt Edgar Link pending
0001564590-21-015518-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwpjrhodncoa000001.jpg Edgar Link pending
gwpjrhodncoa000002.jpg Edgar Link pending
gwpjrhodncoa000003.jpg Edgar Link pending
gwpjrhodncoa000004.jpg Edgar Link pending
gwpjrhodncoa000005.jpg Edgar Link pending
gwpjrhodncoa000006.jpg Edgar Link pending
gwpjrhodncoa000007.jpg Edgar Link pending
gwpjrhodncoa000008.jpg Edgar Link pending
gwpjrhodncoa000009.jpg Edgar Link pending
gwpjrhodncoa000010.jpg Edgar Link pending
gwpjrhodncoa000011.jpg Edgar Link pending
gwpjrhodncoa000012.jpg Edgar Link pending
gwpjrhodncoa000013.jpg Edgar Link pending
gwpjrhodncoa000014.jpg Edgar Link pending
gwpjrhodncoa000015.jpg Edgar Link pending
gwpjrhodncoa000016.jpg Edgar Link pending
gwpjrhodncoa000017.jpg Edgar Link pending
gwpjrhodncoa000018.jpg Edgar Link pending
gwpjrhodncoa000019.jpg Edgar Link pending
gwpjrhodncoa000020.jpg Edgar Link pending
gwpjrhodncoa000021.jpg Edgar Link pending
gwpjrhodncoa000022.jpg Edgar Link pending
gwpjrhodncoa000023.jpg Edgar Link pending
gwpjrhodncoa000024.jpg Edgar Link pending
gwpjrhodncoa000025.jpg Edgar Link pending
gwpjrhodncoa000026.jpg Edgar Link pending
gwpjrhodncoa000027.jpg Edgar Link pending
gwpjrhodncoa000028.jpg Edgar Link pending
gwpjrhodncoa000029.jpg Edgar Link pending
gwpjrhodncoa000030.jpg Edgar Link pending
gwpjrhodncoa000031.jpg Edgar Link pending
gwpjrhodncoa000032.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlay-10k_20201231.htm Edgar Link pending
rlay-20201231.xml Edgar Link completed
rlay-20201231.xsd Edgar Link pending
rlay-20201231_cal.xml Edgar Link unprocessable
rlay-20201231_def.xml Edgar Link unprocessable
rlay-20201231_lab.xml Edgar Link unprocessable
rlay-20201231_pre.xml Edgar Link unprocessable
rlay-ex1010_1012.htm Edgar Link pending
rlay-ex211_904.htm Edgar Link pending
rlay-ex231_1123.htm Edgar Link pending
rlay-ex311_6.htm Edgar Link pending
rlay-ex312_7.htm Edgar Link pending
rlay-ex321_8.htm Edgar Link pending
rlay-ex43_903.htm Edgar Link pending
Show.js Edgar Link pending